SPERMOSENS AB
NNGM:SPERM0.01
SEK
+0.00
(+6.98%)
SPERMOSENS AB
NGM:SPERM
(Nordic Growth Market)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Spermosens AB (SPERM.ST), a Sweden-based medical technology company founded in 2018 and headquartered in Lund, develops and commercializes innovative diagnostic devices for male-factor infertility in the assisted reproductive technology (ART) market; its flagship product, JUNO-Checked, is a patented, automated platform that assesses sperm fertilization capacity by measuring binding to egg cell proteins, enabling clinicians to select optimal IVF or ICSI treatments and reduce treatment cycles. The company targets IVF clinics, sperm banks and veterinary applications globally, with primary operations in the Nordic region and an estimated addressable market of USD 600 million based on over 3 million annual IVF cycles worldwide. Recent developments include a next-generation JUNO-Checked device with faster read-out times developed in collaboration with Flex Medical Solutions for a clinical study approved at Reproductive Medicine Center in Malmö; a SEK 10.8 million directed share issue in early 2025 led by Mount Nebo Capital, UNITY Innovation Alliance and Nordic/German investors to fund commercialization and achieve cash-flow positivity by H2 2026; over 50% operational cost reductions versus 2023 to focus on clinical validation and partnerships; and patent approvals in Mexico and Canada.